Display Settings:

Format

Send to:

Choose Destination
J Thromb Thrombolysis. 2009 Aug;28(2):224-8. doi: 10.1007/s11239-009-0326-2. Epub 2009 Mar 17.

The pharmacodynamics of enoxaparin in percutaneous coronary intervention with precise rapid enoxaparin loading (PEPCI-PRE study).

Author information

  • 1Main Line Health, Sharpe-Strumia Research Foundation, Bryn Mawr Hospital, Bryn Mawr, PA 19010, USA. MartinJ@mlhs.org

Erratum in

  • J Thromb Thrombolysis. 2009 Aug;28(2):229.

Abstract

OBJECTIVE:

We evaluated the early pharmacodynamic profile of the combined 30 mg intravenous and 1 mg/kg subcutaneous enoxaparin loading utilized in the TIMI 11B and ExTRACT TIMI 25 trials.

BACKGROUND:

It has not been reported whether anti-Xa levels appropriate for percutaneous coronary intervention (PCI) can be reliably achieved within 2 h utilizing this regimen.

METHODS:

Twenty-six patients with acute coronary syndrome (ACS) treated with this regimen had anti-Xa levels measured at 5 min, 2, 4, 6 and 8 h.

RESULTS:

Seventy-six percent of patients had anti-Xa levels above 0.5 IU/ml at 5 min. Dose-response curves showed all patients to have anti-Xa levels above 0.5 IU/ml within 1 h. Anti-Xa remained in the targeted range for PCI (0.5 to 1.8 IU/ml) at 2, 4, 6 and 8 h in all patients.

CONCLUSION:

This regimen is well suited for ACS treatment with an invasive strategy, including the rapid transition to early and rescue PCI.

PMID:
19291367
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Springer
    Loading ...
    Write to the Help Desk